High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients

Rollnik, Jens D.; Huber, Thomas J.; Mogk, Hannu; Siggelkow, Sabine; Kropp, Stefan; Dengler, Reinhard; Emrich, Hinderk M.; Schneider, Udo

doi:10.1097/00001756-200012180-00022

Cited by 103 publications

(74 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a randomised, double-blind sham-controlled study high-frequency rTMS over the left dorsolateral prefrontal cortex (DLFPC) resulted in significant improvement compared to sham stimulation in the average BPRS score in 12 schizophrenic patients (Rollnik et al 2000;Huber et al 2003). Another study displayed a trend for a temporary improvement immediately after the application of a single verum 20 Hz rTMS session, persisting until the following day (Nahas et al 1999).…”

Section: Repetitive Transcranial Magnetic Stimulation (Rtms)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A Á/D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.Key words: Schizophrenia, long-term treatment, evidence-based medicine, practice guidelines, biological treatment, antipsychotics EXECUTIVE SUMMARY OF RECOMMENDATIONS General recommendationsSpecific treatment strategies are required not only for patients suffering from acute schizophrenia, but also in the stabilisation and stable phase of the disease. The stabilisation period follows the acute phase and constitutes a time-limited transition to continuing treatment in the stable phase. The stable phase represents a prolonged period of treatment and rehabilitation during which symptoms are under adequate control and the focus is on improving functioning and recovery. The goals of long-term therapy have to be discussed with the patient on the background of adequately provided information and his personal goals in order to find common ground to encourage a long-term medication strategy (shared-decision making). In this regard a treatment plan must be formulated and implemented. During the stabilisation phase, the main goals of treatment are to facilitate continued reduction in symptoms, consolidate remission, and promote the process of recovery. The main goals of treatment during the stable phase are to ensure that symptom remission or control is sustained, that the patient is maintaining or improving the level of functioning and quality of life, to prevent relapse, and to ensure that monitoring for adverse treatment effects continues. The antipsychotic pharmacological therapy should be accompanied by psychosocial interventions. A number of psychosocial...

show abstract

Section: Repetitive Transcranial Magnetic Stimulation (Rtms)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

show abstract

“…[53][54][55][56] The findings were relatively promising; however, the findings were controversial. A meta-analysis review of nine clinical trials (n = 213 patients) showed that active rTMS could significantly improve the negative symptoms of schizophrenia compared with the sham rTMS.…”

Section: Schizophreniamentioning

confidence: 99%

Untitled

Rashidi

2017

AJP

View full text Add to dashboard Cite

Psychiatric disorders are the most common debilitating diseases worldwide. Repetitive transcranial magnetic stimulation (rTMS) has shown therapeutic outcomes in different neurophysiology and neuropsychiatric disorders. Despite controversial findings on the therapeutic outcomes of this technique in different psychiatric disorders, researchers emphasize on developing this technique as an alternative or adjunctive modality for these disorders. Depression, different hallucinations, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and substance abuse are the main disorders have shown good treatment response to rTMS. This study aims to comprehensively overview the applications and recent advances in rTMS applications in psychiatric disorders. The databases of PubMed (1985PubMed ( -2017, Web of Sciences (1985-2017, Embase (1985-2017), Cochrane Central Library (1985-2017), and Google Scholar (1985-2017 were searched using the keywords of repetitive transcranial magnetic stimulation OR rTMS AND psychiatric disorders AND treatment. The retrieved records were reviewed, and the relevant studies were selected for further review. Repeated sessions of low frequency (≤5 Hz) rTMS induce long-lasting neural inhibition or depotentiation, whereas high frequency (>5 Hz) induces long-lasting neural excitability or potentiation. Depending on the neural alteration induced by a disorder, low-or high-frequency rTMS is used for the treatment. The rTMS is approved as acute treatment for major depression. The other diseases with promising outcomes are different hallucinations, OCD, and PTSD. rTMS seems to be an alternative or adjunctive therapeutic modality in different psychiatric disorders. To reach efficient clinical application for each disorder, further randomized clinical trials, as well as preclinical studies, are needed.

show abstract

“…Rollnik et al examined, in a double-blind, crossover design, the effects of higher frequency rTMS delivered to left prefrontal cortex in 12 schizophrenia patients with negative symptoms [13]. In this study, rTMS was delivered to left DLPFC each day for 2 weeks.…”

Section: Effect Of Rtms On Negative Symptomsmentioning

confidence: 99%

Use of Repetitive Transcranial Magnetic Stimulation in Treatment of Negative Symptoms of Schizophrenia

Sayar¹,

Bulut²,

Tarhan³

2015

J Neurol Neurol Sci Disord

View full text Add to dashboard Cite

High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients

Cited by 103 publications

References 4 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Untitled

Use of Repetitive Transcranial Magnetic Stimulation in Treatment of Negative Symptoms of Schizophrenia

Contact Info

Product

Resources

About